scholarly journals Erratum: Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study

Gene Therapy ◽  
2016 ◽  
Vol 23 (8-9) ◽  
pp. 696-696 ◽  
Author(s):  
R Kaminski ◽  
R Bella ◽  
C Yin ◽  
J Otte ◽  
P Ferrante ◽  
...  
Gene Therapy ◽  
2016 ◽  
Vol 23 (8-9) ◽  
pp. 690-695 ◽  
Author(s):  
R Kaminski ◽  
R Bella ◽  
C Yin ◽  
J Otte ◽  
P Ferrante ◽  
...  

2018 ◽  
Vol 9 ◽  
Author(s):  
Mikhail E. Sokolov ◽  
Farid V. Bashirov ◽  
Vage A. Markosyan ◽  
Tatyana V. Povysheva ◽  
Filip O. Fadeev ◽  
...  

2009 ◽  
Vol 7 (5) ◽  
pp. 562-568 ◽  
Author(s):  
Yu-Sen Gao ◽  
Tian-Hua Huang ◽  
Dian Wang ◽  
Qing-Dong Xie ◽  
Xiang-Jin Kang

ChemPhysChem ◽  
2021 ◽  
Vol 22 (10) ◽  
pp. 905-905
Author(s):  
Neil J. Stewart ◽  
Hitomi Nakano ◽  
Shuto Sugai ◽  
Mitsushi Tomohiro ◽  
Yuki Kase ◽  
...  

1994 ◽  
Vol 28 (3) ◽  
pp. 287-291 ◽  
Author(s):  
T. Lazzarotto ◽  
B. Campisi ◽  
M.C. Re ◽  
F. Albertini ◽  
G. Furlini ◽  
...  

ChemPhysChem ◽  
2021 ◽  
Author(s):  
Neil J. Stewart ◽  
Hitomi Nakano ◽  
Shuto Sugai ◽  
Mitsushi Tomohiro ◽  
Yuki Kase ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Shawn Abeynaike ◽  
Silke Paust

With the discovery of antiretroviral therapy, HIV-1 infection has transitioned into a manageable but chronic illness, which requires lifelong treatment. Nevertheless, complete eradication of the virus has still eluded us. This is partly due to the virus’s ability to remain in a dormant state in tissue reservoirs, ‘hidden’ from the host’s immune system. Also, the high mutation rate of HIV-1 results in escape mutations in response to many therapeutics. Regardless, the development of novel cures for HIV-1 continues to move forward with a range of approaches from immunotherapy to gene editing. However, to evaluate in vivo pathogenesis and the efficacy and safety of therapeutic approaches, a suitable animal model is necessary. To this end, the humanized mouse was developed by McCune in 1988 and has continued to be improved on over the past 30 years. Here, we review the variety of humanized mouse models that have been utilized through the years and describe their specific contribution in translating HIV-1 cure strategies to the clinic.


2021 ◽  
Vol 41 ◽  
pp. 02010
Author(s):  
Youdiil Ophinni

The innovation of CRISPR-Cas9 has single-handedly revolutionized biotechnology by enabling efficient and specific cutting of DNA. CRISPR-Cas9 approaches are promising not only to targetthe human genome but also DNA of pathogenic viruses, which coincidentally is the canonical function in its bacterial origin. Since 2014, a myriad of studies has proven the efficacy of CRISPR-Cas9 treatment to cleave viral DNA intermediates in vitro. One of the most widely targeted is theproviral genome of human immunodeficiency virus type-1 (HIV-1). The disease burden of HIV-1 is massive—the infection is incurable and has remained a pandemic for over four decades. Integrated HIV-1 provirus inside the human genome causes viral persistence inside latent cellular reservoirs, eluding antiretroviral therapy (ART) and sterilizing cure. Specific targeting anddisruption of HIV-1 proviral genome is necessary to achieve viral clearance, which can be achieved with CRISPR-Cas9. Here, we review the features and up to date evidence of CRISPRCas9 to target the HIV-1 proviral genome and suppress viral replication. We will also discuss potential CRISPR/Cas9 delivery methods in vivo, combination with other gene editing modalities and other therapeutic approaches, to bring gene editing-based HIV-1 cure closer into clinical use.


Sign in / Sign up

Export Citation Format

Share Document